Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 27Terminated 5Withdrawn 2Recruiting 2Unknown 1No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 2Warts 1Neutropenia 1Lymphoma, Non-Hodgkin 1Leukopenia 1Leukemia, Myeloid, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × plerixafor × Clear all
NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT07188090 2025-11-28

HSCT

Thomas Jefferson University

Phase 2 Recruiting
100 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡